EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TARGETING IMMUNOTHERAPY

  • George Zhu Institute of Oncology, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

EpCAM is a cell adhesion molecule. Its structure, its expression and the oncogenic potential, and its signaling network and target therapy were in concise reviewed. In recent advances, in addition to PI3K/akt and Raf/MAPK pathway involving in cell survival, anti-apoptosis and proliferation,and malignant initiation and progression, three distinct pathway are illustrated: EpCAM/E-cadherin-catenin-actin cytoskeleton, EpCAM/wint-catenin signaling and its major EpCAM/nuclear signaling presented by Maetzel D in 2009 and Munz M in 2004. Moreover, more accumulated data are needed in detail mechanism. The data may provide its cancer biology and clinical targeting therapy benefits.


google_s_2.JPG


Peer Review History:


Received 28 February 2018;   Revised 25 April; Accepted 10 May, Available online 15 May 2018


UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.


Received file


pdf3.JPG


Average Peer review marks at initial stage: 4.5/10


Average Peer review marks at publication stage: 7.5/10


Reviewer(s) detail:


Name: Fatehalrahman F. Magbool


Affiliation: University of Khartoum, Sudan


E-mail: fmagbool@yahoo.com


Comments of reviewer(s):


pdf3.JPG

Keywords: EpCAM, nuclear signaling, structure, target therapy

Author Biography

George Zhu, Institute of Oncology, Tehran University of Medical Sciences, Tehran, Iran.

 

 

Statistics
731 Views | 396 Downloads
How to Cite
Zhu, G. “EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TARGETING IMMUNOTHERAPY”. Universal Journal of Pharmaceutical Research, Vol. 3, no. 2, May 2018, pp. 43-48, doi:https://doi.org/10.22270/ujpr.v3i2.140.
Section
Review Articles